Sensitivity analysis: complete response treatment effect of tisagenlecleucel vs blinatumomab
| Method . | OR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted OR | |||
| Univariate logistic regression | 3.39 | 1.78-6.45 | .0002 |
| Marginal OR (adjusted) | |||
| Logistic regression with sIPTW | 3.46 | 1.82-6.59 | .0002 |
| Logistic regression with trimmed sIPTW | 3.68 | 1.93-7.04 | <.0001 |
| Conditional OR (adjusted) | |||
| Logistic regression stratified by quintiles of propensity score | 3.08 | 1.56-6.09 | .0012 |
| Logistic regression adjusting for prognostic factors | 3.83 | 1.88-7.79 | .0002 |
| Logistic regression adjusting for prognostic factors and propensity score | 3.84 | 1.89-7.83 | .0002 |
| Method . | OR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted OR | |||
| Univariate logistic regression | 3.39 | 1.78-6.45 | .0002 |
| Marginal OR (adjusted) | |||
| Logistic regression with sIPTW | 3.46 | 1.82-6.59 | .0002 |
| Logistic regression with trimmed sIPTW | 3.68 | 1.93-7.04 | <.0001 |
| Conditional OR (adjusted) | |||
| Logistic regression stratified by quintiles of propensity score | 3.08 | 1.56-6.09 | .0012 |
| Logistic regression adjusting for prognostic factors | 3.83 | 1.88-7.79 | .0002 |
| Logistic regression adjusting for prognostic factors and propensity score | 3.84 | 1.89-7.83 | .0002 |
OR is the odds ratio of tisagenlecleucel vs blinatumomab. An OR >1 indicates that tisagenlecleucel is associated with a higher odds of response than blinatumomab.